Literature DB >> 25771770

Animal models of primary biliary cirrhosis.

Tomohiro Katsumi1, Kyoko Tomita, Patrick S C Leung, Guo-Xiang Yang, M Eric Gershwin, Yoshiyuki Ueno.   

Abstract

Primary biliary cirrhosis (PBC) is characterized histologically by the presence of chronic non-suppurative destructive cholangitis of the small interlobular bile duct, leading to chronic progressive cholestasis. Most PBC patients are asymptomatic and have a reasonable prognosis, but a few develop esophageal varices or jaundice, rapidly leading to liver failure within a short period. As multiple factors appear to be involved in the onset of PBC, its clinical course may be complicated. Therefore, the use of an animal model would be valuable for clarifying the pathogenesis of PBC. Here, we review recent data of selected PBC models, particularly spontaneous models, xenobiotic immunized models, and infection-triggered models. There are a number of spontaneous models: the NOD.c3c4, dominant-negative TGF-β receptor II, IL-2Rα-/-, Scurfy, and Ae2a,b-/- mice. These animal models manifest distinct clinical and immunological features similar, but also often different, from those of human PBC. It is clear that a combination of genetic predisposition, environmental factors, and immunological dysfunction contribute to the pathogenesis of PBC. The diverse clinical course and complexity of the immunological mechanisms of PBC cannot be fully recapitulated solely any single animal model. The challenge remains to develop a progressive PBC disease model that exhibits fibrosis, and ultimately hepatic failure.

Entities:  

Mesh:

Year:  2015        PMID: 25771770     DOI: 10.1007/s12016-015-8482-y

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  104 in total

1.  Increased portal tract infiltration of mast cells and eosinophils in primary biliary cirrhosis.

Authors:  A Nakamura; K Yamazaki; K Suzuki; S Sato
Journal:  Am J Gastroenterol       Date:  1997-12       Impact factor: 10.864

2.  Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice.

Authors:  Sabine Oertelt; Zhe-Xiong Lian; Chun-Mei Cheng; Ya-Hui Chuang; Kerstien A Padgett; Xiao-Song He; William M Ridgway; Aftab A Ansari; Ross L Coppel; Ming O Li; Richard A Flavell; Mitchell Kronenberg; Ian R Mackay; M Eric Gershwin
Journal:  J Immunol       Date:  2006-08-01       Impact factor: 5.422

3.  DNA methylation and mRNA and microRNA expression of SLE CD4+ T cells correlate with disease phenotype.

Authors:  Ming Zhao; Siyang Liu; Shuangyan Luo; Honglong Wu; Meini Tang; Wenjing Cheng; Qing Zhang; Peng Zhang; Xinhai Yu; Yudong Xia; Na Yi; Fei Gao; Li Wang; Susan Yung; Tak Mao Chan; Amr H Sawalha; Bruce Richardson; M Eric Gershwin; Ning Li; Qianjin Lu
Journal:  J Autoimmun       Date:  2014-08-03       Impact factor: 7.094

Review 4.  Mechanisms of tissue injury in autoimmune liver diseases.

Authors:  Evaggelia Liaskou; Gideon M Hirschfield; M Eric Gershwin
Journal:  Semin Immunopathol       Date:  2014-08-01       Impact factor: 9.623

5.  Compromised central tolerance of ICA69 induces multiple organ autoimmunity.

Authors:  Yong Fan; Giulio Gualtierotti; Asako Tajima; Maria Grupillo; Antonina Coppola; Jing He; Suzanne Bertera; Gregory Owens; Massimo Pietropaolo; William A Rudert; Massimo Trucco
Journal:  J Autoimmun       Date:  2014-08-01       Impact factor: 7.094

6.  Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis.

Authors:  January T Salas; Jesús M Banales; Sarai Sarvide; Sergio Recalde; Alex Ferrer; Iker Uriarte; Ronald P J Oude Elferink; Jesús Prieto; Juan F Medina
Journal:  Gastroenterology       Date:  2008-02-14       Impact factor: 22.682

7.  Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2Ralpha(-/-) mice.

Authors:  Willy Hsu; Weici Zhang; Koichi Tsuneyama; Yuki Moritoki; William M Ridgway; Aftab A Ansari; Ross L Coppel; Zhe-Xiong Lian; Ian Mackay; M Eric Gershwin
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

8.  Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells.

Authors:  Ana Lleo; Weici Zhang; W Hayes McDonald; Erin H Seeley; Patrick S C Leung; Ross L Coppel; Aftab A Ansari; David H Adams; Simon Afford; Pietro Invernizzi; M Eric Gershwin
Journal:  Hepatology       Date:  2014-07-31       Impact factor: 17.425

9.  Innate immunity drives the initiation of a murine model of primary biliary cirrhosis.

Authors:  Chao-Hsuan Chang; Ying-Chun Chen; Weici Zhang; Patrick S C Leung; M Eric Gershwin; Ya-Hui Chuang
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

10.  Differential modulation by IL-17A of Cholangitis versus Colitis in IL-2Rα deleted mice.

Authors:  Wei Yang; Yuan Yao; Yan-Qing Yang; Fang-Ting Lu; Liang Li; Yin-Hu Wang; Takahiko Nakajima; Koichi Tsuneyama; William M Ridgway; M Eric Gershwin; Zhe-Xiong Lian
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

View more
  31 in total

Review 1.  Environmental basis of primary biliary cholangitis.

Authors:  Atsushi Tanaka; Patrick Sc Leung; M Eric Gershwin
Journal:  Exp Biol Med (Maywood)       Date:  2018-01-07

2.  The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis.

Authors:  Zongwen Shuai; Jinjun Wang; Madhu Badamagunta; Jinjung Choi; Guoxiang Yang; Weici Zhang; Thomas P Kenny; Kathryn Guggenheim; Mark J Kurth; Aftab A Ansari; John Voss; Ross L Coppel; Pietro Invernizzi; Patrick S C Leung; M Eric Gershwin
Journal:  Hepatology       Date:  2017-03-31       Impact factor: 17.425

Review 3.  Current strategies to generate mature human induced pluripotent stem cells derived cholangiocytes and future applications.

Authors:  Eduardo Cervantes-Alvarez; Yang Wang; Alexandra Collin de l'Hortet; Jorge Guzman-Lepe; Jiye Zhu; Kazuki Takeishi
Journal:  Organogenesis       Date:  2017-01-05       Impact factor: 2.500

Review 4.  Xenobiotics and loss of tolerance in primary biliary cholangitis.

Authors:  Jinjun Wang; Guoxiang Yang; Alana Mari Dubrovsky; Jinjung Choi; Patrick S C Leung
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 5.  Inflammatory Bowel Disease: Influence and Implications in Reproduction.

Authors:  Louise E Glover; Blair Fennimore; Mary Wingfield
Journal:  Inflamm Bowel Dis       Date:  2016-11       Impact factor: 5.325

6.  Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance.

Authors:  Heekyong R Bae; Patrick S C Leung; Koichi Tsuneyama; Julio C Valencia; Deborah L Hodge; Seohyun Kim; Tim Back; Megan Karwan; Anand S Merchant; Nobuyuki Baba; Dechun Feng; Ogyi Park; Bin Gao; Guo-Xiang Yang; M Eric Gershwin; Howard A Young
Journal:  Hepatology       Date:  2016-06-15       Impact factor: 17.425

Review 7.  A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis.

Authors:  Patrick S C Leung; Jinjung Choi; Guoxiang Yang; Elena Woo; Thomas P Kenny; M Eric Gershwin
Journal:  Expert Rev Mol Diagn       Date:  2016-03-30       Impact factor: 5.225

8.  Endogenous IL-10 maintains immune tolerance but IL-10 gene transfer exacerbates autoimmune cholangitis.

Authors:  Yu-Hsin Hsueh; Hung-Wen Chen; Bi-Jhen Syu; Chia-I Lin; Patrick S C Leung; M Eric Gershwin; Ya-Hui Chuang
Journal:  J Autoimmun       Date:  2018-09-28       Impact factor: 7.094

9.  MiR-139-5p is associated with inflammatory regulation through c-FOS suppression, and contributes to the progression of primary biliary cholangitis.

Authors:  Tomohiro Katsumi; Masashi Ninomiya; Taketo Nishina; Kei Mizuno; Kyoko Tomita; Hiroaki Haga; Kazuo Okumoto; Takafumi Saito; Tooru Shimosegawa; Yoshiyuki Ueno
Journal:  Lab Invest       Date:  2016-09-26       Impact factor: 5.662

Review 10.  Proposed therapies in primary biliary cholangitis.

Authors:  Annarosa Floreani; Ying Sun; Zheng Sheng Zou; Baosen Li; Nora Cazzagon; Christopher L Bowlus; M Eric Gershwin
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2016-01-06       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.